Nucleoside-based anticancer drugs: Mechanism of action and drug resistance

This publication has 183 references indexed in Scilit:

• A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
  Pharmaceuticals, 2012
• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
  Biochemical Pharmacology, 2012
• Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease
  Inflammatory Bowel Diseases, 2012
• Genetic Variants in Cytosolic 5′-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia
  The Journal of Pharmacology and Experimental Therapeutics, 2011
• Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
  PLOS ONE, 2011
• The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy
  Proceedings of the National Academy of Sciences, 2011
• Biotransformation of 6‐thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6‐thioguanine
  British Journal of Pharmacology, 2011
• 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
  Cancer Research, 2010
• Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism
  Blood, 2008
• Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)
  New England Journal of Medicine, 1948